Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | Mosunetuzumab-axgb |
Trade Name | Lunsumio |
Synonyms | RG7828|BTCT4465A|RO7030816|BTCT-4465A |
Drug Descriptions |
Lunsumio (mosunetuzumab-axgb) is a bispecific antibody targeting CD20 and CD3, which may result in killing of CD20-positive tumor cells (PMID: 25972002, PMID: 29351372). Lunsumio (mosunetuzumab-axgb) is FDA approved for use in adult patients with relapsed or refractory follicular lymphoma who have received two or more lines of systemic therapy (FDA.gov). |
DrugClasses | CD20 Antibody 24 CD3 Antibody 99 |
CAS Registry Number | 1905409-39-3 |
NCIT ID | C129691 |